Curated News
By: NewsRamp Editorial Staff
April 23, 2026
Newron Pharmaceuticals Elects New Board Members at AGM 2026
TLDR
- Newron shareholders gain new independent board members with industry expertise, potentially strengthening strategic direction and pipeline execution.
- Newron's AGM approved new board members George Garibaldi and Paolo Zocchi; extraordinary motions lacked quorum and were not voted.
- Newron advances treatments for neurological disorders like schizophrenia and Parkinson's, aiming to improve patients' quality of life.
- Evenamide, Newron's lead drug candidate, targets treatment-resistant schizophrenia with a novel mechanism and favorable safety profile.
Impact - Why it Matters
This news matters because Newron's progress in developing evenamide for treatment-resistant schizophrenia could address a significant unmet medical need. With clinical data showing sustained efficacy and safety, the drug has the potential to improve outcomes for patients who do not respond to existing antipsychotics. The board refreshment injects fresh expertise, while ongoing partnerships expand global reach. Investors and patients alike should watch for ENIGMA-TRS Phase III results, which could reshape schizophrenia treatment.
Summary
Newron Pharmaceuticals S.p.A., a biopharmaceutical company focused on developing therapies for central and peripheral nervous system diseases, announced that its shareholders approved all motions during the ordinary part of the Annual General Meeting (AGM) held on April 23, 2026. Key approvals included the election of George Garibaldi and Paolo Zocchi as new, independent, non-executive Board members. However, the extraordinary part of the meeting could not proceed due to insufficient quorum. Chairman Chris Martin expressed gratitude to shareholders for their trust and welcomed the new board members, while thanking outgoing directors Patrick Langlois and Luca Benatti for their long-standing service.
Newron is advancing innovative neuroscience treatments, with its lead compound evenamide—a first-in-class glutamate modulator—showing promise as an add-on therapy for treatment-resistant schizophrenia (TRS) and poorly responding schizophrenia patients. The global pivotal ENIGMA-TRS Phase III program is underway, with clinical results demonstrating significant improvements in efficacy measures and a favorable safety profile. The company has secured development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, and with Myung In Pharm for South Korea. Additionally, Newron's marketed product Xadago®/safinamide, for Parkinson's disease, has received marketing authorization in multiple regions, including the EU, US, Japan, and South Korea, and is commercialized by partners Zambon, Supernus Pharmaceuticals, and Meiji Seika.
For more information, visit the company's website at www.newron.com. The original release can be viewed on NEWMEDIAWIRE.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Newron Pharmaceuticals Elects New Board Members at AGM 2026
